US 12,285,608 B2
Anatomical targeting of neuromodulation
Tianhe Zhang, Studio City, CA (US); Bradley Lawrence Hershey, Carrollton, TX (US); and Michael A. Moffitt, Solon, OH (US)
Assigned to Boston Scientific Neuromodulation Corporation, Valencia, CA (US)
Filed by Boston Scientific Neuromodulation Corporation, Valencia, CA (US)
Filed on Oct. 7, 2020, as Appl. No. 17/065,162.
Application 17/065,162 is a continuation of application No. 15/710,190, filed on Sep. 20, 2017, granted, now 10,850,101.
Claims priority of provisional application 62/400,472, filed on Sep. 27, 2016.
Prior Publication US 2021/0016090 A1, Jan. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/36 (2006.01); A61N 1/372 (2006.01); G16H 50/50 (2018.01)
CPC A61N 1/36057 (2013.01) [A61N 1/3605 (2013.01); A61N 1/36062 (2017.08); A61N 1/36071 (2013.01); A61N 1/36092 (2013.01); A61N 1/36103 (2013.01); A61N 1/36132 (2013.01); A61N 1/36185 (2013.01); A61N 1/37247 (2013.01); G16H 50/50 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A neuromodulation targeting system facilitating spatial selection of a neuromodulation objective for a neuromodulation therapy to be delivered by a neuromodulation device, the system comprising:
a graphical user interface (GUI) that includes an interactive display representing anatomy of a patient, wherein the interactive display includes user-selectable anatomic sites associated with a plurality of predefined neural pathways corresponding to distinct localized clinical effects of neuromodulation, wherein the interactive display further includes a user-selectable exclusion zone of the anatomy and a therapy type selector input configured for receiving one or more user-selected, specified neuromodulation therapy types from more than one specified neuromodulation therapy types to be excluded from the user-selectable exclusion zone such that the user-selectable exclusion zone of the anatomy of the patient is to be free of the one or more user-selected, specified neuromodulation therapy types, wherein selection of a first anatomic site and selection of the exclusion zone are separate user selections of anatomical regions of the patient; and
a targeting selector engine operatively coupled with the GUI, the targeting selector engine being responsive to selecting the first anatomic site and the exclusion zone to:
computationally determine a first target region where the neuromodulation therapy is to be directed while keeping the user selected exclusion zone free from the one or more specified neuromodulation therapy types and while allowing application of other neuromodulation therapy types in the user selectable exclusion zone, the first target region being distinct from an anatomic location corresponding to the user-selected first anatomic site, and
configure delivery of the neuromodulation therapy by the neuromodulation device to the first target region to produce a first localized clinical effect in the patient at the anatomic location corresponding to the user-selected first anatomic site, upon administration of the neuromodulation therapy to the patient, to achieve the neuromodulation objective.